UK markets close in 2 hours 42 minutes
  • FTSE 100

    7,199.58
    +77.26 (+1.08%)
     
  • FTSE 250

    22,734.79
    +88.71 (+0.39%)
     
  • AIM

    1,179.19
    -3.11 (-0.26%)
     
  • GBP/EUR

    1.1732
    +0.0042 (+0.36%)
     
  • GBP/USD

    1.3259
    +0.0024 (+0.18%)
     
  • BTC-GBP

    36,391.84
    -1,036.76 (-2.77%)
     
  • CMC Crypto 200

    1,237.24
    -204.52 (-14.19%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.72 (-0.17%)
     
  • CRUDE OIL

    68.34
    +2.08 (+3.14%)
     
  • GOLD FUTURES

    1,782.00
    -1.90 (-0.11%)
     
  • NIKKEI 225

    27,927.37
    -102.20 (-0.36%)
     
  • HANG SENG

    23,349.38
    -417.31 (-1.76%)
     
  • DAX

    15,269.98
    +100.00 (+0.66%)
     
  • CAC 40

    6,829.93
    +64.41 (+0.95%)
     

CMS Grants Transitional Pass-Through (TPT) Payment for Carlsmed's aprevo® Personalized Interbody Devices

·2-min read

CARLSBAD, Calif., October 19, 2021--(BUSINESS WIRE)--Carlsmed announced today that the Center for Medicare & Medicaid Services (CMS) has granted aprevo® a Transitional Pass-Through (TPT) payment as part of the quarterly update of the 2021 Medicare Hospital Outpatient Prospective Payment System. The aprevo® Personalized Interbody Devices were the only devices to receive TPT status in this update. The pass-through payment provides outpatient facilities with an incremental Medicare payment for procedures in which aprevo® is used.

"FDA granted the aprevo® Personalized Interbody Devices Breakthrough Device Designation in 2020 based on the device’s potential to provide a more effective treatment when compared to existing treatment options," said Mike Cordonnier, CEO of Carlsmed. "Having both NTAP and TPT enhanced reimbursement now provides patients access to new technology for inpatient and outpatient spine surgery procedures." The aprevo® New Technology Add-On Payment (NTAP) and Transitional Pass-Through (TPT) payment reimbursement programs took effect on October 1, 2021. A copy of the quarterly update can be found here: https://www.cms.gov/files/document/r10997cp.pdf.

About Carlsmed

Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company’s aprevo® devices are designed to improve the standard of care for the surgical treatment of patients with adult spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices to align with the surgeon’s goals for each patient. The Carlsmed® aprevo® devices are FDA cleared and have been granted FDA Breakthrough Designation, an industry first for any implanted device, and are commercially available in the U.S.

For more information, visit carlsmed.com or contact us at info@carlsmed.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211019006177/en/

Contacts

Jodi Coe
jcoe@carlsmed.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting